Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
18.82
Price to sales ratio
5.35
Dividends per share
5.14
Dividend yield %
2.48

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
10
LLY
Eli Lilly and Company Common Stock
1189.42 USD+0.12%-1.44%+1.99%+50.73%1.12 T USD
24
ABBV
AbbVie Inc. Common Stock
246.53 USD-0.58%-3.93%+8.65%+28.57%435.57 B USD
42
MRK
Merck & Company, Inc. Common Stock
123.53 USD-0.02%-2.80%+1.67%+48.08%305.10 B USD
45
NVS
Novartis AG
153.34 USD-0.46%-1.60%-0.44%+27.35%292.60 B USD

Frequently asked questions about Johnson & Johnson Common Stock

What is the Johnson & Johnson Common Stock stock price today?

The current price of Johnson & Johnson Common Stock (JNJ) is 258.22. Over the past 24 hours, the stock has changed by +0.46%. Follow the JNJ chart for real-time price dynamics.

What is the stock ticker of Johnson & Johnson Common Stock?

Johnson & Johnson Common Stock trades under the ticker JNJ. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Johnson & Johnson Common Stock stock going up?

JNJ has changed by -0.21% over the last week, +7.59% over the last month, and +64.70% over the last year. Review the chart to see whether the current move is part of a broader trend.

Does Johnson & Johnson Common Stock release financial reports?

Yes. You can track Johnson & Johnson Common Stock financial reports and review yearly or quarterly fundamentals on metatrader.com, including revenue, net income, dividends, and valuation metrics.

What was Johnson & Johnson Common Stock net income for the last quarter?

Johnson & Johnson Common Stock reported net income of 5.12 B for the last quarter. The previous quarter showed 5.15 B, which means net income changed by -0.70%.

How many employees does Johnson & Johnson Common Stock have?

As of the latest available data, Johnson & Johnson Common Stock has 140.8 K employees. Workforce size can provide additional context about the company's scale and operations.

What is Johnson & Johnson Common Stock EBITDA?

Johnson & Johnson Common Stock EBITDA is 2.7 B, and its EBITDA margin is 10.98%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Johnson & Johnson Common Stock stock?

You can buy Johnson & Johnson Common Stock (JNJ) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Johnson & Johnson Common Stock stock?

Investing in Johnson & Johnson Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the JNJ chart and related analysis on metatrader.com as part of your research.

Johnson & Johnson Common Stock

Johnson & Johnson is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey. The company operates 2 divisions: Innovative Medicine and MedTech. Major products produced by the Innovative Medicine division are CARVYKTI for multiple myeloma; DARZALEX, also for multiple myeloma; ERLEADA, for prostate cancer; REMICADE, for inflammatory diseases; SIMPONI/SIMPONI ARIA, for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis; STELARA, for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis; TREMFYA, for plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis; INVEGA SUSTENNA/XEPLION, for schizophrenia; SPRAVATO, a nasal spray for depression; OPSUMIT /OPSYNVI for pulmonary arterial hypertension; and UPTRAVI for pulmonary arterial hypertension. The MedTech division produces products used for cardiovascular, orthopaedics, surgery, and vision treatments. The company is ranked 48th on the Fortune 500 and 42nd on the Forbes Global 2000.

News